Log In
Print this Print this

namilumab (MT203)

  Manage Alerts
Collapse Summary General Information
Company Amgen Inc.
DescriptionHuman mAb that neutralizes the proinflammatory cytokine granulocyte macrophage colony-stimulating factor (GM-CSF)
Molecular Target Granulocyte macrophage colony-stimulating factor (GM-CSF) (CSF2)
Mechanism of ActionGranulocyte macrophage colony stimulating factor (GM-CSF) receptor antagonist; Antibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today